Fortress Biotech Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.7
- Today's High:
- $0.75
- Open Price:
- $0.73
- 52W Low:
- $0.48
- 52W High:
- $1.53
- Prev. Close:
- $0.74
- Volume:
- 876800
Company Statistics
- Market Cap.:
- $89.88 million
- Book Value:
- 0.57
- Revenue TTM:
- $77.62 million
- Operating Margin TTM:
- -263.39%
- Gross Profit TTM:
- $-85658000
- Profit Margin:
- -117.49%
- Return on Assets TTM:
- -34.94%
- Return on Equity TTM:
- -143.38%
Company Profile
Fortress Biotech Inc had its IPO on 2011-11-17 under the ticker symbol FBIO.
The company operates in the Healthcare sector and Biotechnology industry. Fortress Biotech Inc has a staff strength of 173 employees.
Stock update
Shares of Fortress Biotech Inc opened at $0.73 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $0.7 - $0.75, and closed at $0.7.
This is a -5.41% slip from the previous day's closing price.
A total volume of 876,800 shares were traded at the close of the day’s session.
In the last one week, shares of Fortress Biotech Inc have slipped by -9.09%.
Fortress Biotech Inc's Key Ratios
Fortress Biotech Inc has a market cap of $89.88 million, indicating a price to book ratio of 1.0999 and a price to sales ratio of 0.8248.
In the last 12-months Fortress Biotech Inc’s revenue was $77.62 million with a gross profit of $-85658000 and an EBITDA of $-197844000. The EBITDA ratio measures Fortress Biotech Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Fortress Biotech Inc’s operating margin was -263.39% while its return on assets stood at -34.94% with a return of equity of -143.38%.
In Q3, Fortress Biotech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 21.6%.
Fortress Biotech Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -0.1
Its diluted EPS in the last 12-months stands at $-1.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.1. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fortress Biotech Inc’s profitability.
Fortress Biotech Inc stock is trading at a EV to sales ratio of 0.0128 and a EV to EBITDA ratio of 0.0737. Its price to sales ratio in the trailing 12-months stood at 0.8248.
Fortress Biotech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $323.56 million
- Total Liabilities
- $106.30 million
- Operating Cash Flow
- $-893000.00
- Capital Expenditure
- $980000
- Dividend Payout Ratio
- 0%
Fortress Biotech Inc ended 2023 with $323.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $323.56 million while shareholder equity stood at $61.67 million.
Fortress Biotech Inc ended 2023 with $0 in deferred long-term liabilities, $106.30 million in other current liabilities, 108000.00 in common stock, $-607090000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $208.35 million and cash and short-term investments were $208.35 million. The company’s total short-term debt was $2,271,000 while long-term debt stood at $92.54 million.
Fortress Biotech Inc’s total current assets stands at $257.99 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $28.53 million compared to accounts payable of $93.82 million and inventory worth $15.23 million.
In 2023, Fortress Biotech Inc's operating cash flow was $-893000.00 while its capital expenditure stood at $980000.
Comparatively, Fortress Biotech Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $0.7
- 52-Week High
- $1.53
- 52-Week Low
- $0.48
- Analyst Target Price
- $8.5
Fortress Biotech Inc stock is currently trading at $0.7 per share. It touched a 52-week high of $1.53 and a 52-week low of $1.53. Analysts tracking the stock have a 12-month average target price of $8.5.
Its 50-day moving average was $0.81 and 200-day moving average was $0.85 The short ratio stood at 0.35 indicating a short percent outstanding of 0%.
Around 3554.7% of the company’s stock are held by insiders while 2797.4% are held by institutions.
Frequently Asked Questions About Fortress Biotech Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company’s early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.